+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
The Global Autoimmune Disease Diagnosis Market is projected to reach USD 8,460.82 million by 2030, from USD 4,309.38 million in 2021 and is anticipated to register a CAGR of 8.0% between 2022 and 2030.
Download Free Report Sample to learn more about this report.
One of the newly growing non-communicable diseases is an autoimmune disease (AD). One major element driving up the adoption rates of autoimmune disease diagnostics globally is the growing awareness about autoimmune illnesses through research, education, support, and activism programs. More than 8 million Americans have psoriasis, according to the National Psoriasis Foundation (2019), and according to the Centers for Disease Control and Prevention, 2018, 10–20% of those who have psoriasis go on to develop psoriatic arthritis or joint inflammation that causes symptoms of arthritis. In order to get a competitive edge, various autoimmune disease diagnostic market participants worldwide are concentrating on new launches and other growth tactics. For example, the EUROIMMUN Anti-Tissue Transglutaminase ELISA from PerkinElmer Inc. was approved by the US Food and Drug Administration in March 2019 for the diagnosis of autoimmune celiac disease.
The unprecedented COVID-19 outbreak caused severe social, health, and economic problems for the entire world. The COVID-19 epidemic has significantly impacted the production of biotechnology, medicines, the pharmaceutical supply chain, and R&D operations in the biotechnology, pharmaceutical, and autoimmune disease diagnosis markets. People were detained in locations where they couldn't travel to offices and laboratories for months due to travel restrictions, which caused pharmaceutical production and supply chain companies to lose a significant amount of money in the first three quarters of 2020. The cessation of the supply of raw materials for research and development has a significant negative impact on research and development activities in the pharmaceutical and biotechnology industries. Investments in pharmaceutical research and development, industrial biotechnology, and biotech R&D were postponed or discontinued, which led to considerable financial stress.
Download Free Report Sample to learn more about this report.
On the basis of Type, the global Autoimmune Disease Diagnosis Market is segmented into antinuclear antibody tests, autoantibody tests, Complete Blood Count (CBC), C - reactive protein (CRP), urinalysis, and others tests
The Antinuclear antibody tests dominated the segment. Antinuclear antibody testing is the most popular diagnostic test for determining whether autoimmune disorders are present in the body. Antibodies are often proteins that fight against invading things like germs and viruses. An antinuclear antibody, so named because it specifically targets the nucleus (center) of healthy cells, on the other hand, assaults your healthy cells.
Additionally, throughout the forecast period, the Autoimmune Disease Diagnosis Market is anticipated to develop due to the presence of numerous industry participants, the introduction of new products, and growing public awareness of the need for early detection and treatment of autoimmune illnesses.
Market Drivers:
Public Awareness and Autoimmune Disorders- The trending issues
According to the National Stem Cell Foundation, more than 80 distinct autoimmune illnesses impact close to 4% of the global population. Of them, type 1 diabetes, rheumatoid arthritis, multiple sclerosis, lupus, Crohn's disease, scleroderma, and psoriasis are the most prevalent. In addition, the incidence and prevalence of these autoimmune illnesses are rising for several causes, including changing lifestyles, stress, nutrition, inactivity, inadequate sleep, and smoking. More than 2.8 million people worldwide, including about 1 million in the United States, are currently living with multiple sclerosis, according to the Atlas of Multiple Sclerosis Report from 2020.
Autoimmune illnesses are becoming more common in European nations, which is another issue. The Multiple Sclerosis Trust estimates that 2.5 million people worldwide have multiple sclerosis, with Europe having the highest prevalence in 2020. Women are more likely than men to get MS. Women are more likely than men to get MS. Rheumatoid arthritis affects two million people. At the same time, psoriasis, one of the most prevalent autoimmune disorders, is thought to impact between 2% and 3% of the general population.
Additionally, the selection of T cells with greater affinity to self-antigens or latent viruses may contribute to the rising frequency of autoimmunity in the aged, which fuels the demand for autoimmune disease diagnostics. According to information from the United Nations' World Population Prospects: The 2019 Revision, the number of adults 65 and older is predicted to more than double by the year 2050, going from 703 million to 1.5 billion. The demographic group 65 years of age and older is growing more quickly than any other age group globally.
In February 2021, The American Kidney Fund (AKF) a new patient-focused education and awareness campaign on lupus nephritis, a form of kidney disease that is caused by lupus. From the AKF’s campaign, people will get information about the treatment and potential signs of lupus nephritis. GSK has provided assistance for the development of AKF’s campaign.
Technological Advancements And Improved Laboratory Automation
An exciting challenge is the study of autoimmune disorders. Numerous autoimmune diseases are characterized by the presence of autoantibodies, a defining and essential feature of autoimmune diseases. Traditionally, biological fluids have been examined for the company and concentration of certain antibodies to analyze the autoimmune response. However, the simultaneous identification and assessment of several autoantibodies in the sera of patients with autoimmune disorders are now possible because of new proteomic techniques.
Due to the development of simultaneous measurement techniques, there is an improvisation of analytical factors, logistical/managerial elements, pathophysiology factors, etc.. Antigen microarrays and mass spectrometry for antibody profiling are two recent approaches that have demonstrated improved analytical sensitivity and repeatability. They can therefore be used in routine clinical procedures.
The identification of biomarkers and their use in clinical practice for diagnostic and therapeutic decisions have been greatly accelerated by the development of genomic and proteomic multiplex technologies. These advancements are speeding up research and development in the industry for diagnosing autoimmune diseases.
As per July 2020 research study published by researchers at the School of Chemistry and Material Science at the University of Science and Technology of China (USTC), nanomedicine is one of the medical fields emerging fields, where you can find highly effective solution for type 1 diabetes. It will bring transformation to the treatment for diabetic patients.
Moreover, the introduction of laboratory automation, which reduces human error, increases productivity, decreases turnaround time, reduces the number of handling steps, etc., is a crucial factor in improving usage rates. Along with automation, integration and consolidation of the methods have simplified the testing process and improved testing accuracy.
The development of automated indirect immunofluorescence, automated multiplex immunoassays for autoantibody profiling, automated monoplex immunoassays with faster turnaround times, and changes to the two-step strategy for autoantibody detection were all made possible by the introduction of automation in the auto immunology laboratory. The market for autoimmune disease diagnostics is expected to grow significantly during the forecast period as a result of the factors mentioned above. In addition, automated immunofluorescence (IIF) and third-generation monoplex immunoassays (IMA) allow for the rapid detection of autoantibodies in terms of minutes or hours, as opposed to days or weeks according to the requirements of manual IMA and IIF methods.
Market Restraints:
Slow Turnaround Time Of Results And Need For Multiple Diagnostic Tests
Autoimmune disease diagnosis takes a lot of time. It entails steps like serum testing for conditions including Hashimoto's disease, Addison's disease, and rheumatoid arthritis. Due to the lack of a single laboratory test to confirm such a diagnosis, examining patients for suspected autoimmune illnesses can be challenging. Usually, several laboratory tests are required, such as a complete blood count, a thorough metabolic panel, acute phase reactants, immunologic studies, serologies, flow cytometry, cytokine analysis, and HLA typing, in addition to basic investigations like a complete blood count. Even though some tests, such as the erythrocyte sedimentation rate (ESR), may not be able to identify a particular disease, they are nonetheless used to gauge disease activity. Diagnosing autoimmune disorders is a time-consuming process involving numerous tests because the results of non-specific tests, like ESR, cannot reveal any information regarding the type of disease. In addition to aiding in diagnosing and treating individuals with autoimmune illnesses, these tests may also help in determining a prognosis or the degree of organ involvement or damage.
Autoimmune Disease Diagnosis Market Opportunities and Future Trends
It is anticipated that rivalry would intensify in response to the rising demand for accurate and sophisticated autoimmune disease diagnosis. The Autoimmune Disease Diagnostics Market also shows a large amount of room for new competitors. It is anticipated that the growing market for novel and enhanced autoimmune diagnostics would open up opportunities for new competitors.
North America has covered a large share in the market during the prediction.
The Autoimmune Disease Diagnosis Market is expanding primarily as a result of the increasing prevalence of chronic diseases, the large patient pool, greater awareness, and rising healthcare costs. The USA has the highest number of autoimmune disorders cases that includes with more than 30 million patients in 2020. The two funding opportunities for autoimmune disease research through the Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases (AMP AIM) initiative were announced by the National Institutes of Health (NIH) in March 2021.
Download Free Report Sample to learn more about this report.
Autoimmune Disease Diagnosis Market Competitive Landscape
Some of the major key player operating in the Autoimmune Disease Diagnosis Market are Thermo Fisher Scientific (US), Siemens (Germany), Abbott (US), Danaher (US), Bio-Rad Laboratories (US), Grifols (Spain), Trinity Biotech (Ireland), Werfen (Spain), EUROIMMUN AG (Germany), Oncimmune (UK), HTG Molecular Diagnostics (United States), HYCOR Biomedical (United States), Seramun Diagnostica GmbH (Germany), Cambridge Life Sciences Limited (UK), A. ORGENTEC Diagnostika (Germany), AESKU.GROUP GMBH & CO.(Germany), and KRONUS (US).
Report Scope
The global autoimmune disease diagnosis market is projected to reach USD 8,460.82 million by 2030, from USD 4,309.38 million in 2021 and is anticipated to register a CAGR of 8.0% between 2022 and 2030.
The North America region is expected to dominate the global Autoimmune Disease Diagnosis Market in 2030
The Antinuclear antibody tests dominated the segment.
Key Companies of the global Autoimmune Disease Diagnosis Market are Thermo Fisher Scientific (US), Siemens (Germany), Abbott (US), Danaher (US), Bio-Rad Laboratories (US), Grifols (Spain), Trinity Biotech (Ireland), Werfen (Spain), EUROIMMUN AG (Germany), Oncimmune (UK), HTG Molecular Diagnostics (United States), HYCOR Biomedical (United States), Seramun Diagnostica GmbH (Germany), Cambridge Life Sciences Limited (UK), A. ORGENTEC Diagnostika (Germany), AESKU.GROUP GMBH & CO.(Germany), and KRONUS (US).
The market is expected to grow CAGR of 8.0% during forecast period 2022-2028
Report Code :
RL6513
Published on :
Nov 2022
Request a Free Sample Report
Speak to Analyst